vs
Amplify Energy Corp.（AMPY）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Amplify Energy Corp.的季度营收约是REGENXBIO Inc.的1.9倍（$56.6M vs $30.3M），Amplify Energy Corp.净利率更高（113.9% vs -221.3%，领先335.2%），REGENXBIO Inc.同比增速更快（43.0% vs -18.1%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -13.9%）
安普利法能源公司是一家原油能源企业，总部位于美国得克萨斯州休斯顿，成立于2017年，目前在纽约证券交易所挂牌上市，核心业务围绕原油领域开展，是美国本土颇具规模的独立能源生产商。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
AMPY vs RGNX — 直观对比
营收规模更大
AMPY
是对方的1.9倍
$30.3M
营收增速更快
RGNX
高出61.1%
-18.1%
净利率更高
AMPY
高出335.2%
-221.3%
两年增速更快
RGNX
近两年复合增速
-13.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $56.6M | $30.3M |
| 净利润 | $64.4M | $-67.1M |
| 毛利率 | 93.7% | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 113.9% | -221.3% |
| 营收同比 | -18.1% | 43.0% |
| 净利润同比 | 967.0% | -31.2% |
| 每股收益（稀释后） | $1.55 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPYRGNX
| Q4 25 | $56.6M | $30.3M | ||
| Q3 25 | $66.4M | $29.7M | ||
| Q2 25 | $68.4M | $21.4M | ||
| Q1 25 | $72.0M | $89.0M | ||
| Q4 24 | $69.0M | $21.2M | ||
| Q3 24 | $69.9M | $24.2M | ||
| Q2 24 | $79.5M | $22.3M | ||
| Q1 24 | $76.3M | $15.6M |
净利润AMPYRGNX
| Q4 25 | $64.4M | $-67.1M | ||
| Q3 25 | $-21.0M | $-61.9M | ||
| Q2 25 | $6.4M | $-70.9M | ||
| Q1 25 | $-5.9M | $6.1M | ||
| Q4 24 | $-7.4M | $-51.2M | ||
| Q3 24 | $22.7M | $-59.6M | ||
| Q2 24 | $7.1M | $-53.0M | ||
| Q1 24 | $-9.4M | $-63.3M |
毛利率AMPYRGNX
| Q4 25 | 93.7% | — | ||
| Q3 25 | 92.1% | — | ||
| Q2 25 | 93.1% | — | ||
| Q1 25 | 94.1% | — | ||
| Q4 24 | 93.5% | 70.2% | ||
| Q3 24 | 93.9% | 48.8% | ||
| Q2 24 | 93.8% | 52.5% | ||
| Q1 24 | 93.7% | 72.6% |
营业利润率AMPYRGNX
| Q4 25 | — | -190.0% | ||
| Q3 25 | -39.9% | -176.3% | ||
| Q2 25 | 18.4% | -296.3% | ||
| Q1 25 | -5.5% | 13.6% | ||
| Q4 24 | -9.6% | -242.1% | ||
| Q3 24 | 46.7% | -256.6% | ||
| Q2 24 | 17.0% | -251.3% | ||
| Q1 24 | -11.9% | -408.8% |
净利率AMPYRGNX
| Q4 25 | 113.9% | -221.3% | ||
| Q3 25 | -31.6% | -208.3% | ||
| Q2 25 | 9.3% | -331.8% | ||
| Q1 25 | -8.1% | 6.8% | ||
| Q4 24 | -10.8% | -241.3% | ||
| Q3 24 | 32.4% | -246.3% | ||
| Q2 24 | 9.0% | -237.7% | ||
| Q1 24 | -12.3% | -405.4% |
每股收益（稀释后）AMPYRGNX
| Q4 25 | $1.55 | $-1.30 | ||
| Q3 25 | $-0.52 | $-1.20 | ||
| Q2 25 | $0.15 | $-1.38 | ||
| Q1 25 | $-0.15 | $0.12 | ||
| Q4 24 | $-0.16 | $-0.99 | ||
| Q3 24 | $0.54 | $-1.17 | ||
| Q2 24 | $0.17 | $-1.05 | ||
| Q1 24 | $-0.24 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $60.7M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $458.7M | $102.7M |
| 总资产 | $600.9M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMPYRGNX
| Q4 25 | $60.7M | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | $502.0K | $290.4M | ||
| Q1 24 | $3.0M | $338.7M |
股东权益AMPYRGNX
| Q4 25 | $458.7M | $102.7M | ||
| Q3 25 | $393.0M | $161.5M | ||
| Q2 25 | $411.3M | $213.7M | ||
| Q1 25 | $402.9M | $274.2M | ||
| Q4 24 | $408.9M | $259.7M | ||
| Q3 24 | $414.7M | $301.4M | ||
| Q2 24 | $390.3M | $348.3M | ||
| Q1 24 | $381.0M | $390.7M |
总资产AMPYRGNX
| Q4 25 | $600.9M | $453.0M | ||
| Q3 25 | $731.4M | $525.2M | ||
| Q2 25 | $771.3M | $581.0M | ||
| Q1 25 | $753.6M | $490.9M | ||
| Q4 24 | $747.1M | $466.0M | ||
| Q3 24 | $739.2M | $519.1M | ||
| Q2 24 | $720.4M | $569.4M | ||
| Q1 24 | $712.2M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-13.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | -0.21× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流AMPYRGNX
| Q4 25 | $-13.4M | $-52.3M | ||
| Q3 25 | $13.4M | $-56.0M | ||
| Q2 25 | $23.7M | $-49.3M | ||
| Q1 25 | $25.5M | $33.6M | ||
| Q4 24 | $12.5M | $-31.6M | ||
| Q3 24 | $15.7M | $-40.5M | ||
| Q2 24 | $15.4M | $-45.5M | ||
| Q1 24 | $7.7M | $-55.5M |
自由现金流AMPYRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率AMPYRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度AMPYRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率AMPYRGNX
| Q4 25 | -0.21× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.71× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.69× | — | ||
| Q2 24 | 2.16× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPY
| Oil And Gas | $54.7M | 97% |
| Other | $1.8M | 3% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
